ArticleMedical oncology (Northwood, London, England)2012
Polymorphic CA repeat length in insulin-like growth factor 1 and risk of breast cancer in Iranian women.
Article in Medical oncology (Northwood, London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Associations of BCL2 CA-Repeat Polymorphism and Breast Cancer Susceptibility in Isfahan Province of Iran.Biochemical genetics · 2021Article
- Genetic and molecular biology of breast cancer among Iranian patients.Journal of translational medicine · 2019Review
- Microsatellite polymorphism in the P1 promoter region of the IGF‑1 gene is associated with endometrial cancer.Molecular medicine reports · 2016Article
- The role of the insulin-like growth factor-1 system in breast cancer.Molecular cancer · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the association between breast cancer and cytosine-adenine (CA) dinucleotide repeat length polymorphisms in the promoter region of the Insulin-like Growth Factor 1 (IGF-1) gene, a case-control study of 215 breast cancer patients and 224 controls was conducted in Iranian women. The most common allele and genotype in both controls and patients were an allele length of 19 and a homozygous genotype of (CA)(19)/(CA)(19). Women with two alleles longer than 19 were found to be at a higher risk of breast cancer with an odds ratio of 4.1 (P = 0.0002). In contrast, women with two alleles shorter than 20 were at lower risk of breast cancer. These results suggest a novel association between CA repeat length in IGF-1 and risk of breast cancer.
Indexed as
Identifiers
21484083What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.